Skip to main content
← All research

Best-Selling Immunology Drugs in Q3 2026: Revenue Leaders and Market Dynamics

Best-Selling Immunology Drugs in Q3 2026: Revenue Leaders and Market Dynamics

The 10 best-selling immunology drugs generated $24.3B in worldwide sales in Q3 2026, 18% more than the same drugs sold in Q3 2025. Growth is concentrated at the top, as Dupixent, Skyrizi, and Rinvoq together accounted for $15.0B, or 62% of the total.

This report ranks the leaders by Q3 2026 sales and covers the three shifts behind the numbers, which are Dupixent's widening lead, AbbVie's completed move beyond Humira, and Johnson & Johnson's handover from Stelara to Tremfya.

Bar chart of the 10 best-selling immunology drugs by Q3 2026 sales with the change from Q3 2025. Dupixent leads at $6.54B, and the top 10 grew 18% to $24.3B.

Top-selling immunology drugs in Q3 2026

RankDrugCompanyQ3 2026 salesQ3 2025 salesChange
1DupixentSanofi / Regeneron$6.54B$4.86B+35%
2SkyriziAbbVie$5.78B$4.71B+23%
3RinvoqAbbVie$2.71B$2.18B+24%
4TremfyaJohnson & Johnson$2.40B$1.42B+68%
5CosentyxNovartis$1.86B$1.70B+9%
6EntyvioTakeda$1.72B$1.67B+3%
7OrenciaBristol Myers Squibb$0.98B$0.96B+2%
8TaltzEli Lilly$0.86B$0.90B-5%
9StelaraJohnson & Johnson$0.72B$1.57B-54%
10BenlystaGSK$0.70B$0.60B+16%

Dupixent widens its lead

Dupixent generated $6.5B in Q3 2026, up 35% at constant exchange rates, and its US sales grew 40%. Sanofi attributes part of the US growth to favorable gross-to-net price adjustments, and the drug is now $0.8B a quarter ahead of Skyrizi, its nearest competitor.

AbbVie's post-Humira portfolio is now 12 times Humira

Skyrizi ($5.8B, up 23%) and Rinvoq ($2.7B, up 24%) together generated $8.5B in the quarter, 12 times the $0.68B that Humira earned. During the quarter the FDA approved subcutaneous induction dosing for Skyrizi in Crohn's disease, and Rinvoq reported Phase 3 data in vitiligo.

Tremfya replaces Stelara at Johnson & Johnson

Tremfya grew 68% to $2.4B, whereas Stelara fell 54% to $0.72B after biosimilar entry, so Tremfya now sells 3.3 times as much as its predecessor. Johnson & Johnson says Stelara's decline reduced its Innovative Medicine growth by about 690 basis points, although its total immunology sales still grew 1.3% to $4.2B.

Mature biologics grow slowly and face pricing pressure

Cosentyx grew 9% to $1.9B, driven by hidradenitis suppurativa and spondyloarthritis, and Entyvio grew 3% in dollars to $1.7B, supported by its subcutaneous form. Lilly's Taltz fell 5% to $0.86B.

Older US brands outside the top 10 are under more pressure. Amgen reports a 14% fall in Enbrel's net selling price, which it ties to Medicare price setting under the Inflation Reduction Act from 2026, and Humira's sales fell 31% to $0.68B. Newer launches remain small, as Lilly's Ebglyss generated $0.20B and Bristol Myers Squibb's Sotyktu $0.10B in the quarter.

Implications

Immunology growth now depends on a few franchises that are still adding indications, as the top 3 drugs grew 23% to 35% while most mature biologics grew in single digits or declined. Stelara's 54% fall, within 2 years of its first US biosimilar launch, shows how quickly a leading position erodes once exclusivity ends.

Teams that track quarterly sales across companies often compare several data sources, and our Maven Bio vs Evaluate comparison sets out how the two differ.

Methodology: Sales are Q3 2026 (July to September) worldwide product sales from each company's quarterly report, compared with Q3 2025. Immunology covers drugs whose core indications are autoimmune or immune-mediated inflammatory diseases of the skin, joints, or gut, or systemic autoimmune disease, and excludes respiratory and allergy biologics (Xolair, Nucala, Fasenra, Tezspire) and neurology drugs such as Vyvgart and Ocrevus. Dupixent is Sanofi-recorded sales. Non-USD sales are converted at the Federal Reserve's average rate for each quarter, so changes are in US dollars. Takeda's Entyvio quarter is derived from its first-half and first-quarter reports. UCB's Bimzelx is not included because UCB reports sales only for half-years.

Research your next biopharma question with Maven.